Alexza Pharmaceuticals Inc
ALXA
ALXA was delisted on the 16th of June, 2016.
41 hedge funds and large institutions have $30.7M invested in Alexza Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 8 closing their positions.
2,755% more call options, than puts
Call options by funds: $5.88M | Put options by funds: $206K
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
0% more capital invested
Capital invested by funds: $30.6M → $30.7M (+$151K)
0% more funds holding
Funds holding: 41 → 41 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.94M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$614K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$175K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$128K |
| 5 |
Morgan Stanley
New York
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$244K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$212K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$127K |
| 4 |
VM
VHCP Management
New York
|
-$123K |
| 5 |
Jane Street
New York
|
-$111K |
ALXA Hedge Fund Activity: Q4 2013 in Review
41 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Alexza Pharmaceuticals Inc (ALXA) for Q4 2013, worth a combined $30.7M — up 0.49% from $30.6M a quarter earlier.
Fund positioning in ALXA was balanced in Q4 2013: 8 funds opened new positions, 8 closed out, 13 added to existing stakes and 9 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.94M. The largest seller was Vanguard Group, cutting an estimated $244K.
- 41 institutional investors held Alexza Pharmaceuticals Inc (ALXA) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $30.7M of Alexza Pharmaceuticals Inc stock for Q4 2013, up 0.49% quarter-over-quarter.
- 8 funds opened new Alexza Pharmaceuticals Inc positions in Q4 2013 and 8 closed out, a net change of 0 holders.
- The largest Alexza Pharmaceuticals Inc buyer in Q4 2013 was Goldman Sachs, an estimated $1.94M added.
- The largest Alexza Pharmaceuticals Inc seller in Q4 2013 was Vanguard Group, an estimated $244K sold.
Based on aggregated 13F filings for Q4 2013.